X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1036) 1036
beta-alanine - analogs & derivatives (992) 992
dabigatran (801) 801
index medicus (730) 730
beta-alanine - therapeutic use (634) 634
benzimidazoles - therapeutic use (606) 606
male (442) 442
anticoagulants - therapeutic use (437) 437
rivaroxaban (377) 377
female (351) 351
beta-alanine - adverse effects (335) 335
benzimidazoles - adverse effects (324) 324
warfarin (321) 321
atrial fibrillation - drug therapy (288) 288
stroke - prevention & control (283) 283
thiophenes - therapeutic use (283) 283
aged (282) 282
morpholines - therapeutic use (279) 279
beta-alanine - administration & dosage (249) 249
anticoagulants (245) 245
warfarin - therapeutic use (241) 241
atrial fibrillation - complications (226) 226
atrial fibrillation (225) 225
administration, oral (222) 222
benzimidazoles - administration & dosage (221) 221
pyrazoles - therapeutic use (216) 216
pyridones - therapeutic use (216) 216
anticoagulants - adverse effects (215) 215
antithrombins - therapeutic use (202) 202
animals (200) 200
middle aged (191) 191
anticoagulants - administration & dosage (179) 179
stroke (166) 166
hemorrhage - chemically induced (162) 162
beta-alanine - pharmacology (157) 157
cardiac & cardiovascular systems (148) 148
pharmacology & pharmacy (148) 148
treatment outcome (148) 148
stroke - etiology (146) 146
dabigatran etexilate (142) 142
abridged index medicus (139) 139
atrial-fibrillation (135) 135
aged, 80 and over (133) 133
antithrombins - adverse effects (133) 133
peripheral vascular disease (128) 128
medicine, general & internal (125) 125
prevention (125) 125
venous thromboembolism (119) 119
apixaban (116) 116
etexilate (114) 114
morpholines - adverse effects (113) 113
thiophenes - adverse effects (113) 113
hematology (109) 109
risk factors (108) 108
anticoagulation (103) 103
thrombin (100) 100
morpholines - administration & dosage (99) 99
thiophenes - administration & dosage (99) 99
warfarin - adverse effects (99) 99
adult (95) 95
direct thrombin inhibitor (93) 93
drug therapy (89) 89
antithrombins - administration & dosage (88) 88
risk (88) 88
thromboembolism - prevention & control (87) 87
pyrazoles - administration & dosage (85) 85
pyrazoles - adverse effects (85) 85
thromboembolism (85) 85
beta-alanine - pharmacokinetics (84) 84
pyridones - adverse effects (84) 84
pyridones - administration & dosage (83) 83
stroke prevention (83) 83
beta-alanine (78) 78
therapy (77) 77
pharmacokinetics (76) 76
rats (75) 75
venous thromboembolism - prevention & control (75) 75
management (74) 74
benzimidazoles - pharmacology (69) 69
randomized controlled trials as topic (69) 69
dose-response relationship, drug (68) 68
factor xa inhibitors (68) 68
medicine & public health (68) 68
analysis (67) 67
biochemistry & molecular biology (66) 66
care and treatment (66) 66
risk assessment (66) 66
warfarin - administration & dosage (65) 65
beta-alanine - blood (63) 63
mice (63) 63
benzimidazoles - pharmacokinetics (62) 62
vitamin k - antagonists & inhibitors (61) 61
venous thromboembolism - drug therapy (60) 60
clinical trials as topic (58) 58
surgery (57) 57
beta-alanine - economics (56) 56
international normalized ratio (56) 56
neurosciences (56) 56
reversal (56) 56
benzimidazoles - economics (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1049) 1049
Japanese (41) 41
German (30) 30
Spanish (27) 27
French (23) 23
Italian (5) 5
Russian (5) 5
Chinese (4) 4
Danish (4) 4
Finnish (4) 4
Hungarian (3) 3
Czech (2) 2
Polish (2) 2
Swedish (2) 2
Dutch (1) 1
Portuguese (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 7, p. CD006650
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2012, Volume 110, Issue 3, pp. 453 - 460
Journal Article
Stroke, ISSN 0039-2499, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 03/2015, Volume 131, Issue 11, pp. 972 - 979
BACKGROUND—Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the kidneys. Their use in dialysis patients is discouraged... 
Rivaroxaban | Warfarin | Dialysis | Dabigatran | Atrial fibrillation | dialysis | atrial fibrillation | CARDIAC & CARDIOVASCULAR SYSTEMS | dabigatran | RISK | PERIPHERAL VASCULAR DISEASE | rivaroxaban | warfarin | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | beta-Alanine - pharmacokinetics | Hospitalization - statistics & numerical data | Warfarin - adverse effects | Male | Risk | Drug Utilization | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Practice Patterns, Physicians' - statistics & numerical data | Kidney - metabolism | Matched-Pair Analysis | Aged, 80 and over | Female | Retrospective Studies | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Databases, Factual | beta-Alanine - adverse effects | Kidney - drug effects | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Benzimidazoles - pharmacokinetics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Kidney Failure, Chronic - metabolism | Warfarin - pharmacokinetics | Practice Patterns, Physicians' - trends | Atrial Fibrillation - metabolism | Thiophenes - pharmacokinetics | Stroke - etiology | Kidney Failure, Chronic - complications | Poisson Distribution | Aged | Anticoagulants - pharmacokinetics | Hemorrhage - chemically induced | Morpholines - pharmacokinetics | Renal Dialysis
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 09/2012, Volume 108, Issue 3, pp. 476 - 484
New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation. Two... 
anticoagulants | Stroke | Atrial fibrillation | Review Article | Anticoagulants | COST-EFFECTIVENESS | EVENTS | STROKE PREVENTION | RISK | PHARMACODYNAMICS | stroke | PHARMACOKINETICS | WARFARIN | ORAL ANTICOAGULANTS | ANTITHROMBOTIC THERAPY | ETEXILATE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Warfarin - adverse effects | Male | Secondary Prevention | Dabigatran | Thrombophilia - etiology | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Ischemic Attack, Transient - prevention & control | Clinical Trials, Phase III as Topic - statistics & numerical data | Heart Valve Diseases - complications | Female | Stroke - epidemiology | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Embolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Thrombophilia - drug therapy | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Severity of Illness Index | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Stroke - prevention & control | beta-Alanine - adverse effects | Embolism - prevention & control | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Antithrombins - therapeutic use | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ischemic Attack, Transient - epidemiology | Antithrombins - adverse effects | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects
Journal Article